Axsome Therapeutics Inc’s recently made public that its Chief Executive Officer TABUTEAU HERRIOT unloaded Company’s shares for reported $13.48 million on Jan 05 ’26. In the deal valued at $171.28 per share,78,703 shares were sold. As a result of this transaction, TABUTEAU HERRIOT now holds 7,229 shares worth roughly $1.26 million.
Then, TABUTEAU HERRIOT sold 31,261 shares, generating $5,326,249 in total proceeds. Upon selling the shares at $170.38, the Chief Executive Officer now owns 7,229 shares.
Before that, TABUTEAU HERRIOT sold 29,450 shares. Axsome Therapeutics Inc shares valued at $5,075,118 were divested by the Chief Executive Officer at a price of $172.33 per share. As a result of the transaction, TABUTEAU HERRIOT now holds 7,229 shares, worth roughly $1.26 million.
Morgan Stanley downgraded its Axsome Therapeutics Inc [AXSM] rating to an Equal-weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock fall -1.41% to $174.33. Over the last five days, the stock has gained 1.43%. Axsome Therapeutics Inc shares have risen nearly 117.78% since the year began. Nevertheless, the stocks have fallen -4.55% over the past one year.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-12-31, dropping by -0.68 million shares to a total of 2.72 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 3.4 million shares. There was a decline of -25.0%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 03, 2025 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $185 price target.
